AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32753377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (RR, 2.0-4.6)
Number of subjects: 140
Study 32753377 — intervention group
Group type: COMPARATOR
Intervention: Normal-risk group
Number of subjects: 140
Study 32753377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (Ductal endoscopy)
Number of subjects: 140
Study 32753377 — intervention group
Group type: COMPARATOR
Intervention: Normal-risk group (Ductal endoscopy)
Number of subjects: 140
Study 32753395 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAR Pathway risk assessments (HEAR scores and serial troponin testing at 0 and 3 hours)
Number of subjects: 4979
Study 32753397 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialidosis type I patients
Number of subjects: 7
Study 32753543 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor therapy (CIT)
Number of subjects: 0
Study 32753546 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 300 mg QD Days 1-14 (cycles 1-3 only) + durvalumab 1500 mg IV day 15 (regimen A)
Number of subjects: 28
Study 32753546 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 100 mg QD days 1-21 + vitamin C 500 mg once a day continuously + durvalumab 1500 mg IV day 15 (regimen B)
Number of subjects: 28
Study 32753620 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipocyte fatty acid binding protein (A-FABP)
Number of subjects: 0
Study 32753620 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 0
Study 32753624 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with newly acquired SCI
Number of subjects: 35
Study 32753849 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) antipsychotics
Number of subjects: 1402
Study 32753849 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid injection
Number of subjects: 1402
Study 32753849 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly dosing
Number of subjects: 1402
Study 32753875 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment with any FDA approved or cleared device
Number of subjects: 689
Study 32753879 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib (400 mg po qd)
Number of subjects: 1
Study 32754110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasimelteon (HETLIOZ®); dosage and duration not available
Number of subjects: 0
Study 32754110 — intervention group
Group type: COMPARATOR
Intervention: Placebo; dosage and duration not available
Number of subjects: 0
Study 32754307 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 1031
Study 32755241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (Turalio™) taken orally
Number of subjects: 0
Study 32755471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral nitrite therapy (40 mg/3× daily)
Number of subjects: 20
Study 32755608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological stimulation targeting β2-adrenergic receptors (β2-AR); specific dosage and duration not mentioned.
Number of subjects: 0
Study 32755885 — intervention group
Group type: EXPERIMENTAL
Intervention: m2Hear
Number of subjects: 16
Study 32755884 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM group (smartphone app with wearable activity tracker)
Number of subjects: 73
Study 32755891 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-adapted CISSS-CA ACE program
Number of subjects: 1635
Study 32755891 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiki-suite
Number of subjects: 1635
Study 32756330 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sedentary Behavior (SB)
Number of subjects: 9218
Study 32756876 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive vaccination
Number of subjects: 1478
Study 32756876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconsecutive vaccination
Number of subjects: 1478
Study 32756938 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 32756938 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 0
Study 32756938 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 0
Study 32756984 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-coagulation
Number of subjects: 144
Study 32756984 — intervention group
Group type: EXPERIMENTAL
Intervention: History of myocardial infarction
Number of subjects: 144
Study 32756984 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed HALT volume
Number of subjects: 144
Study 32756984 — intervention group
Group type: EXPERIMENTAL
Intervention: HALT
Number of subjects: 144
Study 32757505 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32757642 — intervention group
Group type: EXPERIMENTAL
Intervention: PA pressure-guided therapy
Number of subjects: 1200
Study 32757661 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamondback 360 Micro Crown Coronary OAS
Number of subjects: 100
Study 32757661 — intervention group
Group type: COMPARATOR
Intervention: Classic Crown Orbital Atherectomy System (OAS)
Number of subjects: 100
Study 32757806 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive history assessment
Number of subjects: 0
Study 32757824 — intervention group
Group type: COMPARATOR
Intervention: L-alone (8-session diet and physical activity lifestyle intervention)
Number of subjects: 26
Study 32757824 — intervention group
Group type: EXPERIMENTAL
Intervention: L+Sleep (L-alone plus a behavioral sleep intervention)
Number of subjects: 26
Study 32757824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (L-alone and L+Sleep)
Number of subjects: 26
Study 32757853 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR TKI sequencing
Number of subjects: 0
Study 32758177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on the Three-Talk model, including a patient decision aid and decision coaching meetings
Number of subjects: 349
Study 32758177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on the Three-Talk model
Number of subjects: 349
Study 32758188 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stereotactic body radiotherapy (SBRT) with a total dose of 36 Gy in 6 fractions over 2 weeks
Number of subjects: 90
Study 32758188 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stereotactic body radiotherapy (SBRT)
Number of subjects: 90
Study 32758293 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic expanded umbilical cord-derived mesenchymal stem cells (UC-MSCs)
Number of subjects: 0
Study 32758293 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow-derived cells (from previous studies)
Number of subjects: 0
Study 32758387 — intervention group
Group type: EXPERIMENTAL
Intervention: bioprosthetic autoregulated artificial heart
Number of subjects: 0
Study 32758434 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide (3.0 mg as formulated capsules) plus Obinutuzumab (1000 mg)
Number of subjects: 73
Study 32758434 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide (various doses) plus Obinutuzumab (1000 mg)
Number of subjects: 73
Study 32758438 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care workers screened for IgM and IgG antibodies against SARS-CoV-2
Number of subjects: 28292
Study 32758438 — intervention group
Group type: COMPARATOR
Intervention: Health-care workers
Number of subjects: 28292
Study 32758438 — intervention group
Group type: EXPERIMENTAL
Intervention: Male health-care workers
Number of subjects: 28292
Study 32758438 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontline health-care workers in hospitals
Number of subjects: 28292
Study 32758438 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care workers on dedicated COVID-19 wards
Number of subjects: 28292
Study 32758438 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive health-care workers
Number of subjects: 28292
Study 32758438 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with loss of taste or smell
Number of subjects: 28292
Study 32758441 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of facemasks during the COVID-19 pandemic
Number of subjects: 0
Study 32758563 — intervention group
Group type: EXPERIMENTAL
Intervention: Hanging-induced cardiac arrest
Number of subjects: 886
Study 32758563 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival at hospital discharge
Number of subjects: 886
Study 32758563 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable neurocognitive outcome
Number of subjects: 886
Study 32758563 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with hospital mortality
Number of subjects: 886
Study 32759178 — intervention group
Group type: EXPERIMENTAL
Intervention: NEOS score
Number of subjects: 111
Study 32759248 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement system analysis in ALS patients
Number of subjects: 0
Study 32759248 — intervention group
Group type: COMPARATOR
Intervention: Complement system analysis in neurologically healthy controls
Number of subjects: 0
Study 32759248 — intervention group
Group type: COMPARATOR
Intervention: Complement system analysis in non-ALS neurological controls
Number of subjects: 0
Study 32759249 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 32759265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 12410
Study 32759265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 12410
Study 32759300 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir cessation based on serum HBV RNA and HBsAg levels
Number of subjects: 114
Study 32759300 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HBV RNA ≥44.6 U/mL
Number of subjects: 114
Study 32759300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HBV RNA undetectability and HBsAg <10 IU/mL
Number of subjects: 114
Study 32759300 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-treatment ALT elevation
Number of subjects: 114
Study 32759300 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg seroclearance
Number of subjects: 114
Study 32759360 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 207817
Study 32759360 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitors
Number of subjects: 207817
Study 32760319 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (walking) for 10 to 30 minutes
Number of subjects: 0
Study 32760832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (150-300 mg/daily)
Number of subjects: 23
Study 32761088 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe short-term hypothyroidism
Number of subjects: 17
Study 32761088 — intervention group
Group type: COMPARATOR
Intervention: Thyroid hormone supplementation after 20 weeks (median TSH 0.03 mU/L)
Number of subjects: 17
Study 32761122 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA treatment for replicating HCV infections
Number of subjects: 3715
Study 32761122 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescreening for HCV-RNA
Number of subjects: 3715
Study 32761122 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-elimination program
Number of subjects: 3715
Study 32761122 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV incidence rate
Number of subjects: 3715
Study 32761193 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score incorporating biomarkers (IL-6, IL-10, IL-27, sCD14, interferon-γ, tumor necrosis factor-α, hyaluronic acid, D-dimer, body mass index, hemoglobin)
Number of subjects: 0
Study 32761193 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline inflammatory profile and changes in inflammatory networks among biomarkers
Number of subjects: 0
Study 32761207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum INSL3 measurements
Number of subjects: 18
Study 32761207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum testosterone measurements
Number of subjects: 18
Study 32761207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum INSL3 and testosterone measurements
Number of subjects: 18
Study 32761207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum LH measurements
Number of subjects: 18
Study 32761398 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentation of the fascia lata (FL)
Number of subjects: 73
Study 32761612 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated microspheres
Number of subjects: 641
Study 32761612 — intervention group
Group type: COMPARATOR
Intervention: Non-enteric coated pancreatic enzyme preparations
Number of subjects: 641
Study 32761864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative heparin dose
Number of subjects: 837
Study 32761864 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT measured before sheath removal
Number of subjects: 837
Study 32762056 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study 32762394 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid treatment
Number of subjects: 260
Study 32762457 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual visits
Number of subjects: 0
Study 32762457 — intervention group
Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 0
Study 32762458 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA (375 μmol/L mean)
Number of subjects: 6507
Study 32762458 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA (highest quartile)
Number of subjects: 6507
Study 32762644 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand When You Can (SWYC) intervention
Number of subjects: 10
Study 32762662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) combined with external beam radiotherapy (EBRT)
Number of subjects: 125
Study 32762706 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa treatment
Number of subjects: 5
Study 32762706 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure respiratory support (PEEP ≥6 cm H2O)
Number of subjects: 5
Study 32762980 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32763071 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe LVOT calcification
Number of subjects: 1635
Study 32763071 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable valves with moderate or severe LVOT calcification
Number of subjects: 1635
Study 32763073 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioned group (Evolut R or PRO valve with repositioning)
Number of subjects: 946
Study 32763073 — intervention group
Group type: COMPARATOR
Intervention: Nonrepositioned group (Evolut R or PRO valve without repositioning)
Number of subjects: 946
Study 32763152 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal test-and-treat (UTT) intervention
Number of subjects: 975
Study 32763431 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra implantation in precluded patients
Number of subjects: 546
Study 32763431 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra implantation in nonprecluded patients
Number of subjects: 546
Study 32763431 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber TV-PPM
Number of subjects: 546
Study 32763874 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy children and adolescents (PEF and FEV1 variability assessment)
Number of subjects: 200
Study 32763874 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and adolescents with asthma (PEF and FEV1 variability assessment)
Number of subjects: 200
Study 32763882 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care HIV-1 RNA testing combined with standard rapid antibody tests; 12 months follow-up for clinical outcomes.
Number of subjects: 1500
Study 32763882 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted HIV partner notification services; 12 months follow-up for clinical outcomes.
Number of subjects: 1500
Study 32763882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention period; follow-up for viral suppression by month 6 and month 12 following ART initiation.
Number of subjects: 1500
Study 32763882 — intervention group
Group type: COMPARATOR
Intervention: Observation period; standard care without the intervention.
Number of subjects: 1500
Study 32763967 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational simulation arm (experimental)
Number of subjects: 200
Study 32763967 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm (control)
Number of subjects: 200
Study 32764098 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed motor function measures
Number of subjects: 69
Study 32764098 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype
Number of subjects: 69
Study 32764098 — intervention group
Group type: EXPERIMENTAL
Intervention: c.826C>A mutation
Number of subjects: 69
Study 32764098 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-meter walk/run
Number of subjects: 69
Study 32764098 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor function in adults
Number of subjects: 69
Study 32764775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (> 100 up to 325 mg daily)
Number of subjects: 69911
Study 32764775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 69911
Study 32764775 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 69911
Study 32764775 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (≤ 100 mg daily)
Number of subjects: 69911
Study 32764775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 69911
Study 32764775 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 69911
Study 32764775 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 69911
Study 32764908 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 0
Study 32764908 — intervention group
Group type: COMPARATOR
Intervention: BUD/FOR
Number of subjects: 0
Study 32765053 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane (3 mL)
Number of subjects: 69
Study 32765053 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic treatment (SAT; IV paracetamol 1 g or ketoprofen 100 mg for moderate pain [NRS 4-6] and IV morphine 0.1mg/kg for severe pain [NRS ≥7])
Number of subjects: 69
Study 32765053 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane
Number of subjects: 69
Study 32765053 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic treatment (SAT)
Number of subjects: 69
Study 32765052 — intervention group
Group type: EXPERIMENTAL
Intervention: PECSII block with 30mL of bupivacaine 0.25%
Number of subjects: 180
Study 32765052 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB) with 30mL of bupivacaine 0.25%
Number of subjects: 180
Study 32765052 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 180
Study 32765056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin (7.5 mg twice daily for moderate renal impairment; 7.5 mg once daily for severe renal impairment)
Number of subjects: 35
Study 32765056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin
Number of subjects: 35
Study 32765156 — intervention group
Group type: EXPERIMENTAL
Intervention: Subspecialist treatment for severe asthma
Number of subjects: 936
Study 32765189 — intervention group
Group type: EXPERIMENTAL
Intervention: New perioperative practice model (NPPM)
Number of subjects: 0
Study 32765189 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative care (control)
Number of subjects: 0
Study 32766181 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0
Study 32766181 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 32766383 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day postexposure prophylaxis with oseltamivir
Number of subjects: 222
Study 32766383 — intervention group
Group type: COMPARATOR
Intervention: 10-day postexposure prophylaxis with oseltamivir
Number of subjects: 222
Study 32766469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of nerve growth factor (NGF) into the right masseter muscle on days 0 and 2.
Number of subjects: 150
Study 32766469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain diaries completed twice daily from day 0 to day 30.
Number of subjects: 150
Study 32766725 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of ciprofloxacin 500 mg
Number of subjects: 106
Study 32766875 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg on days 1 and 15 of a 28-day cycle
Number of subjects: 21
Study 32766875 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 21
Study 32766882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum CGM
Number of subjects: 16
Study 32766882 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro CGM
Number of subjects: 16
Study 32766882 — intervention group
Group type: COMPARATOR
Intervention: Meals ranked by Abbott CGM
Number of subjects: 16
Study 32766882 — intervention group
Group type: COMPARATOR
Intervention: Meals ranked by Dexcom CGM
Number of subjects: 16
Study 32766882 — intervention group
Group type: EXPERIMENTAL
Intervention: Kendall rank correlation coefficient
Number of subjects: 16
Study 32766882 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing glycemic reduction
Number of subjects: 16
Study 32766885 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine supplementation at 12 g/d (Study 1)
Number of subjects: 80
Study 32766885 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine supplementation at 16 g/d (Study 2)
Number of subjects: 80
Study 32766885 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine supplementation (4, 8, and 12 g/d in Study 1)
Number of subjects: 80
Study 32766885 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine supplementation (16 g/d in Study 2)
Number of subjects: 80
Study 32766890 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF (daily oral coformulated emtricitabine and tenofovir disoproxil fumarate)
Number of subjects: 48
Study 32766944 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow pathway (SP) ablation
Number of subjects: 45
Study 32766953 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban < 48 h (Early group)
Number of subjects: 686